tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

EDIT Stock Latest News

Editas Medicine Unveils Promising Preclinical Data on EDIT-401
Company AnnouncementsEditas Medicine Unveils Promising Preclinical Data on EDIT-401
20h ago
8K
EDIT
Editas Medicine reports in vivo preclinical PoC data for EDIT-401
PremiumThe Fly
Editas Medicine reports in vivo preclinical PoC data for EDIT-401
1d ago
EDIT
KalVista appoints Bilal Arif as COO, Linea Aspesi as CPO
PremiumThe Fly
KalVista appoints Bilal Arif as COO, Linea Aspesi as CPO
4d ago
EDIT
KALV
Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
PremiumThe Fly
Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
21d ago
V
MA
Editas Medicine price target raised to $4 from $3 at Wells Fargo
PremiumThe Fly
Editas Medicine price target raised to $4 from $3 at Wells Fargo
1M ago
EDIT
Editas Medicine Advances EDIT-401 for LDL Reduction
PremiumCompany AnnouncementsEditas Medicine Advances EDIT-401 for LDL Reduction
1M ago
8K
EDIT
Editas Medicine nominates EDIT-401 as lead in vivo development candidate
Premium
The Fly
Editas Medicine nominates EDIT-401 as lead in vivo development candidate
1M ago
EDIT
Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability
Premium
Ratings
Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability
2M ago
EDIT
Editas Medicine price target raised to $5 from $3 at H.C. Wainwright
PremiumThe Fly
Editas Medicine price target raised to $5 from $3 at H.C. Wainwright
2M ago
EDIT
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch
PremiumCompany Announcements
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch
2M ago
EDIT
Editas Medicine Reports Q2 2025 Progress and Financials
PremiumCompany Announcements
Editas Medicine Reports Q2 2025 Progress and Financials
2M ago
EDIT
Editas Medicine price target raised to $6 from $4 at Baird
PremiumThe Fly
Editas Medicine price target raised to $6 from $4 at Baird
2M ago
EDIT
Editas Medicine reports Q2 EPS (63c), consensus (38c)
PremiumThe FlyEditas Medicine reports Q2 EPS (63c), consensus (38c)
2M ago
EDIT
Editas Medicine Unveils Promising Gene Editing Data
Premium
Company Announcements
Editas Medicine Unveils Promising Gene Editing Data
4M ago
8K
EDIT
Promising Outlook for Editas Medicine: Strong Preclinical Data and Projected Financial Success
Premium
Ratings
Promising Outlook for Editas Medicine: Strong Preclinical Data and Projected Financial Success
4M ago
EDIT
Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells
PremiumThe Fly
Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells
4M ago
EDIT
Editas Medicine Stockholders Approve Key Amendments
PremiumCompany Announcements
Editas Medicine Stockholders Approve Key Amendments
4M ago
8K
EDIT
Prime Medicine price target lowered to $12 from $16 at Chardan
PremiumThe Fly
Prime Medicine price target lowered to $12 from $16 at Chardan
5M ago
EDIT
PRME
Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations
PremiumRatings
Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations
5M ago
EDIT
Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine
PremiumRatingsPromising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine
5M ago
EDIT
Editas Medicine Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Editas Medicine Reports Q1 2025 Progress and Financials
5M ago
EDIT
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
Premium
The Fly
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
5M ago
EDIT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >